Neuropace, Inc. (NPCE)

From the record

Neuropace, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Neuropace, Inc.'s 6 filed years say what it did: revenue went from $41 million in fiscal 2020 to $100 million in fiscal 2025, up 19.4% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 0 of 6 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Neuropace, Inc. lost about 113 cents for every dollar of shareholders' money, and gross profitability: its products earned about 73 cents per dollar of everything the company owns. Leverage: it owed about 82 cents per dollar of assets, and net share issuance: its share count grew 12.3% over the year (the filed statements).

From the record

Neuropace, Inc.'s standing among 109 graded names in its industry family: revenue of $100 million in fiscal 2025 ranks in the top 46% by size; a net margin of -21.5% ranks in the bottom 50%; revenue growth of 30% a year over the last 3 filed years ranks in the top 25% (its annual reports).

From the record

Neuropace, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Becker, Joel (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2023-07-19, 3.3 years (bottom 42% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 5.3 years (bottom 48%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 22%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Neuropace, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $22 million against debt of $59 million leaves -35.1% of its assets as net cash, bottom 4% of its family; cash from operations less capital spending is -11.3% of revenue (bottom 49%); a gross margin of 77.2% (top 15%); research spending of 27.9% of revenue (top 34%) (its annual report).

From the record

Neuropace, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 30% a year over the last three filed years against 19.4% over all 6, speeding up (top 12% of its family); the newest year grew 25.1% (top 27%); research spending grew 8.3% a year (top 43%); capital spending grew -18% a year (bottom 31%) (its annual reports). Neuropace, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Neuropace, Inc.'s newest year against its own record: revenue of $100 million in fiscal 2025 came in 5.5% below the $106 million its prior three years' pace pointed to (bottom 42% of its family); net income of $21 million against a prior three-year average of $36 million (top 39%); a net margin of -21.5% against -62.6% before (top 21%) (its annual reports).